Logo image of PHR

PHREESIA INC (PHR) Stock Fundamental Analysis

NYSE:PHR - New York Stock Exchange, Inc. - US71944F1066 - Common Stock - Currency: USD

24.34  -0.15 (-0.61%)

After market: 24.34 0 (0%)

Fundamental Rating

4

PHR gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 37 industry peers in the Health Care Technology industry. The financial health of PHR is average, but there are quite some concerns on its profitability. While showing a medium growth rate, PHR is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year PHR has reported negative net income.
PHR had a positive operating cash flow in the past year.
PHR had negative earnings in each of the past 5 years.
In multiple years PHR reported negative operating cash flow during the last 5 years.
PHR Yearly Net Income VS EBIT VS OCF VS FCFPHR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 -50M -100M -150M

1.2 Ratios

Looking at the Return On Assets, with a value of -15.07%, PHR is in line with its industry, outperforming 54.05% of the companies in the same industry.
With a Return On Equity value of -22.10%, PHR perfoms like the industry average, outperforming 54.05% of the companies in the same industry.
Industry RankSector Rank
ROA -15.07%
ROE -22.1%
ROIC N/A
ROA(3y)-33.2%
ROA(5y)-26.37%
ROE(3y)-45.91%
ROE(5y)-35.28%
ROIC(3y)N/A
ROIC(5y)N/A
PHR Yearly ROA, ROE, ROICPHR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 2025 0 500 1K

1.3 Margins

The Gross Margin of PHR (67.86%) is better than 70.27% of its industry peers.
In the last couple of years the Gross Margin of PHR has remained more or less at the same level.
PHR does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 67.86%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.16%
GM growth 5Y1.12%
PHR Yearly Profit, Operating, Gross MarginsPHR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50

More info and screens

6

2. Health

2.1 Basic Checks

PHR does not have a ROIC to compare to the WACC, probably because it is not profitable.
PHR has more shares outstanding than it did 1 year ago.
The number of shares outstanding for PHR has been increased compared to 5 years ago.
The debt/assets ratio for PHR is higher compared to a year ago.
PHR Yearly Shares OutstandingPHR Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M
PHR Yearly Total Debt VS Total AssetsPHR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

2.2 Solvency

An Altman-Z score of 4.96 indicates that PHR is not in any danger for bankruptcy at the moment.
PHR has a Altman-Z score of 4.96. This is amongst the best in the industry. PHR outperforms 81.08% of its industry peers.
The Debt to FCF ratio of PHR is 1.95, which is an excellent value as it means it would take PHR, only 1.95 years of fcf income to pay off all of its debts.
PHR's Debt to FCF ratio of 1.95 is amongst the best of the industry. PHR outperforms 81.08% of its industry peers.
A Debt/Equity ratio of 0.03 indicates that PHR is not too dependend on debt financing.
The Debt to Equity ratio of PHR (0.03) is better than 62.16% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF 1.95
Altman-Z 4.96
ROIC/WACCN/A
WACC10.82%
PHR Yearly LT Debt VS Equity VS FCFPHR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M 300M 400M

2.3 Liquidity

PHR has a Current Ratio of 1.78. This is a normal value and indicates that PHR is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of PHR (1.78) is comparable to the rest of the industry.
A Quick Ratio of 1.78 indicates that PHR should not have too much problems paying its short term obligations.
PHR has a Quick ratio of 1.78. This is comparable to the rest of the industry: PHR outperforms 59.46% of its industry peers.
Industry RankSector Rank
Current Ratio 1.78
Quick Ratio 1.78
PHR Yearly Current Assets VS Current LiabilitesPHR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 13.56% over the past year.
PHR shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 17.82%.
PHR shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 27.46% yearly.
EPS 1Y (TTM)13.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%47.62%
Revenue 1Y (TTM)17.82%
Revenue growth 3Y25.34%
Revenue growth 5Y27.46%
Sales Q2Q%15.45%

3.2 Future

Based on estimates for the next years, PHR will show a very strong growth in Earnings Per Share. The EPS will grow by 39.51% on average per year.
PHR is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.64% yearly.
EPS Next Y77.81%
EPS Next 2Y49.05%
EPS Next 3Y39.51%
EPS Next 5YN/A
Revenue Next Year13.62%
Revenue Next 2Y12.75%
Revenue Next 3Y12.62%
Revenue Next 5Y11.64%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
PHR Yearly Revenue VS EstimatesPHR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M
PHR Yearly EPS VS EstimatesPHR Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 -1 -2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PHR. In the last year negative earnings were reported.
Also next year PHR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PHR Price Earnings VS Forward Price EarningsPHR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -50 -100

4.2 Price Multiples

The rest of the industry has a similar Price/Free Cash Flow ratio as PHR.
Industry RankSector Rank
P/FCF 172.51
EV/EBITDA N/A
PHR Per share dataPHR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

A more expensive valuation may be justified as PHR's earnings are expected to grow with 39.51% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y49.05%
EPS Next 3Y39.51%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PHR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PHREESIA INC

NYSE:PHR (5/22/2025, 8:04:00 PM)

After market: 24.34 0 (0%)

24.34

-0.15 (-0.61%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)03-12 2025-03-12/amc
Earnings (Next)05-28 2025-05-28/amc
Inst Owners99.8%
Inst Owner Change-2.04%
Ins Owners5.25%
Ins Owner Change-3.29%
Market Cap1.43B
Analysts85.56
Price Target32.92 (35.25%)
Short Float %4.19%
Short Ratio4.44
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)23.88%
Min EPS beat(2)8.94%
Max EPS beat(2)38.81%
EPS beat(4)4
Avg EPS beat(4)22.42%
Min EPS beat(4)8.94%
Max EPS beat(4)38.81%
EPS beat(8)8
Avg EPS beat(8)22.4%
EPS beat(12)12
Avg EPS beat(12)21.82%
EPS beat(16)14
Avg EPS beat(16)4.17%
Revenue beat(2)0
Avg Revenue beat(2)-0.43%
Min Revenue beat(2)-0.56%
Max Revenue beat(2)-0.3%
Revenue beat(4)0
Avg Revenue beat(4)-0.55%
Min Revenue beat(4)-0.75%
Max Revenue beat(4)-0.3%
Revenue beat(8)3
Avg Revenue beat(8)0.19%
Revenue beat(12)7
Avg Revenue beat(12)0.67%
Revenue beat(16)11
Avg Revenue beat(16)2.64%
PT rev (1m)-1.21%
PT rev (3m)2.45%
EPS NQ rev (1m)0%
EPS NQ rev (3m)3.32%
EPS NY rev (1m)0%
EPS NY rev (3m)22.75%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.27%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.11%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.41
P/FCF 172.51
P/OCF 44.18
P/B 5.4
P/tB 13.24
EV/EBITDA N/A
EPS(TTM)-1.02
EYN/A
EPS(NY)-0.23
Fwd EYN/A
FCF(TTM)0.14
FCFY0.58%
OCF(TTM)0.55
OCFY2.26%
SpS7.14
BVpS4.51
TBVpS1.84
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -15.07%
ROE -22.1%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 67.86%
FCFM 1.98%
ROA(3y)-33.2%
ROA(5y)-26.37%
ROE(3y)-45.91%
ROE(5y)-35.28%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.16%
GM growth 5Y1.12%
F-Score6
Asset Turnover1.08
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF 1.95
Debt/EBITDA N/A
Cap/Depr 86.38%
Cap/Sales 5.74%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.78
Quick Ratio 1.78
Altman-Z 4.96
F-Score6
WACC10.82%
ROIC/WACCN/A
Cap/Depr(3y)91.68%
Cap/Depr(5y)107.3%
Cap/Sales(3y)7.37%
Cap/Sales(5y)9.81%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)13.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%47.62%
EPS Next Y77.81%
EPS Next 2Y49.05%
EPS Next 3Y39.51%
EPS Next 5YN/A
Revenue 1Y (TTM)17.82%
Revenue growth 3Y25.34%
Revenue growth 5Y27.46%
Sales Q2Q%15.45%
Revenue Next Year13.62%
Revenue Next 2Y12.75%
Revenue Next 3Y12.62%
Revenue Next 5Y11.64%
EBIT growth 1Y57.43%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year236.17%
EBIT Next 3Y65.19%
EBIT Next 5Y35.77%
FCF growth 1Y114.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y200.01%
OCF growth 3YN/A
OCF growth 5Y108.09%